Zoetis Inc (ZTS) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Total Assets Chart for Zoetis Inc
Zoetis Inc (ZTS) total assets for FY2025 were USD 15.5B, a 8.6% change from FY2024. Zoetis Inc's total assets grew from USD 5.3B in 2010 to USD 15.5B in 2025 (192.7% over 15 years). Total assets compound annual growth rate: 5-year CAGR of 2.6%, 10-year CAGR of 6.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $30.49B
- Implied Share Price
- $73.79
- Enterprise Value
- $38.06B
- Revenue (TTM)
- $9.53B
- EBITDA
- $4.07B
- Profit Margin
- 27.69%
- Trailing P/E
- 12.04
- Forward P/E
- 11.90
- Price/Book (MRQ)
- 9.69
- Price/Sales (TTM)
- 3.20
- EV/EBITDA
- 9.47
- EV/Revenue
- 4.00
- Dividend Yield
- 2.72%
- Book Value
- $7.84
- Free Cash Flow (FY2025)
- $2.28B
- Free Cash Flow Yield
- 7.49%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.